Pragmatic Clinical Trials and EVOLVE-MI with Dr Christopher Cannon

12/12/22 • 21 min

We would love to hear your thoughts on the episodes!

Dr Christopher Cannon discusses the potential of Pragmatic Clinical Trials in our research armamentarium with Dr. Thomas Nero. They review the EVOLVE-MI trial for Early use of Evolocumab after Myocardial Infarction in detail and highlight the potential for future research.

We would love to hear your thoughts on the episodes!

Previous Episode

Spontaneous Coronary Artery Dissection (SCAD) with Dr. Sharonne Hayes Part 2

We would love to hear your thoughts on the episodes!

Dr Sharoanne Hayes and Dr. Thomas Nero continue their discussion of SCAD focusing on genetics, trial design and the role of online registries as well as the holistic treatment of the SCAD patient. This is part two of two.

Next Episode

Inflammation and Coronary Artery Disease with Dr Paul Ridker

We would love to hear your thoughts on the episodes!

Dr Paul Ridker discusses his paper on residual inflammatory risk that was recently published in the Lancet with Dr. Thomas Nero. He discusses the pathology of inflammation as part of atherosclerosis, utilization of hs-CRP in clinical trials and in daily practice as well as current therapeutic options and ongoing investigations.

Future Pulse Cardiology - Pragmatic Clinical Trials and EVOLVE-MI with Dr Christopher Cannon

Transcript

Welcome to Future Pulse. Today I have the pleasure of speaking with Dr. Christopher Cannon. Dr. Cannon is the Director of Education at the Cardiovascular Innovation Division at the Brigham and Women's Hospital in Boston, Massachusetts. He is a professor of medicine at Harvard Medical School and senior physician at the Brigham. I'm sure he is well known to most of us and is as he is throughout the world for his work, which has included over a thousand papers, 18 textbooks, as well as principal